Pharmaceutical

Devimistat by Cornerstone Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of Approval

Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Soft Tissue Sarcoma.

Dec 24, 2023 - 18:00
Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Soft Tissue Sarcoma.
Read the original article

Tags:

Previous Article

Enzalutamide by Pfizer for Fallopian Tube Cancer: Likelihood of Approval

Next Article

(Nanatinostat + valganciclovir) by Viracta Therapeutics for Solid Tumor: Likelih...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Winners and losers from Medicare’s list of drugs subject to price negotiation

STAT+: Winners and losers from Medicare’s list of drugs...

Aug 29, 2023

After AdCom rejection, FDA rebuffs Novo Nordisk’s once-weekly insulin

After AdCom rejection, FDA rebuffs Novo Nordisk’s once-...

Jul 12, 2024

Japan approves updated Covid-19 vaccine to tackle JN.1 variant

Japan approves updated Covid-19 vaccine to tackle JN.1 ...

Sep 14, 2024